GlassScriptPhysician profile
Ann Kelly
NPI 1104270651
$3,376.74
in general payments reported to CMS, 2019-2025
42 companies · $878 in 2025
The $878 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $68.46 · 2021: $394 · 2022: $395 · 2023: $668 · 2024: $973 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,519.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,038.28 | 2021-2025 | |
| Lilly USA, LLC | $259.47 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $245.93 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $188.52 | 2021-2025 | Farxiga, Airsupra |
| Supernus Pharmaceuticals, INC. | $172.74 | 2023-2025 | Qelbree, Qelbree |
| Pfizer INC. | $146.58 | 2023-2025 | |
| Glaxosmithkline, LLC. | $118.11 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $75.50 | 2020-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $74.51 | 2020-2022 | |
| Noven Therapeutics, LLC | $64.51 | 2024-2025 | Xelstrym |
| Astellas Pharma US INC | $55.73 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $50.01 | 2023 | Gemtesa |
| Esperion Therapeutics, INC. | $48.82 | 2021-2025 | Nexletol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $48.74 | 2025 | Caplyta |
| Amgen INC. | $47.23 | 2024 | Repatha, Otezla |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $46.08 | 2022 | |
| Novartis Pharmaceuticals Corporation | $43.96 | 2022 | |
| Neos Therapeutics, LP | $42.69 | 2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $40.88 | 2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.00 | 2020-2025 | Jardiance |
| Medtronic, INC. | $38.65 | 2023-2025 | Interstim |
| Merck Sharp & Dohme LLC | $37.86 | 2023-2025 | Gardasil 9, Capvaxive |
| Corium, LLC | $37.61 | 2023 | Azstarys |
| Intuitive Surgical, INC. | $34.97 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.28 | 2024-2025 | Xifaxan |
| Dexcom, INC. | $30.71 | 2025 | Dexcom G6 Transmitter |
| Sonex Health, INC. | $30.46 | 2025 | Sx-One Microknife |
| Eisai INC. | $27.13 | 2024 | |
| Sunovion Pharmaceuticals INC. | $23.42 | 2022 | |
| Abbott Laboratories | $22.93 | 2025 | Freestyle Libre 3 |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.46 | 2025 | Rexulti |
| Axonics, INC. | $20.53 | 2023 | Axonics |
| Irhythm Technologies, INC. | $20.41 | 2024 | Zio Xt Patch, Zio Monitor |
| Exact Sciences Corporation | $19.56 | 2025 | Cologuard Collection Kit |
| Alkermes, INC. | $19.41 | 2025 | Vivitrol |
| Shield Therapeutics INC | $19.27 | 2024 | |
| Inari Medical, INC. | $18.05 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Phathom Pharmaceuticals, INC. | $17.31 | 2024 | Voquezna |
| Organon LLC | $16.17 | 2025 | Nexplanon |
| Edwards Lifesciences Corporation | $15.26 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Biohaven Pharmaceuticals, INC. | $12.08 | 2021 | |
| Currax Pharmaceuticals LLC | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.